Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Klaus V Toyka

Showing results (1-10 of 121) with videos related to

Pageof 13
Sort By:
Neurology|October 25, 2006
Ptosis in myasthenia gravis: extended fatigue and recovery bedside testKlaus V Toyka
Neurology|April 23, 2003
The pathogenesis of CIDP: rationale for treatment with immunomodulatory agentsKlaus V Toyka, Ralf Gold
The Lancet. Neurology|July 21, 2004
Immune-mediated components of hereditary demyelinating neuropathies: lessons from animal models and patientsRudolf Martini, Klaus V Toyka
Annals of the New York Academy of Sciences|November 1, 2017
Nerve Conduction Abnormalities and Neuromyotonia in Genetically Engineered Mouse Models of Human Hereditary NeuropathiesJürgen Zielasek, Klaus V Toyka
Annals of Neurology|July 3, 2003
Oculomotor signs in Lambert-Eaton myasthenic syndrome-coincidence with myasthenia gravisKlaus V Toyka, Christiane Schneider-Gold
European Neurology|January 23, 2002
Does Down's syndrome protect against multiple sclerosis?Franz X Weilbach, Klaus V Toyka
Neuroscience Letters|November 15, 2002
Differential blocking effects of the monoclonal anti-GQ1b IgM antibody and alpha-latrotoxin in the absence of complement at the mouse neuromuscular junctionBrigitte Buchwald, Raheleh Ahangari, Klaus V Toyka
Muscle & Nerve|February 15, 2007
Novel SOD1 N86K mutation is associated with a severe phenotype in familial ALSMarcus Beck, Michael Sendtner, Klaus V Toyka
The Cochrane Database of Systematic Reviews|December 14, 2012
Intravenous immunoglobulin for myasthenia gravisPhilippe Gajdos, Sylvie Chevret, Klaus V Toyka
Annals of Neurology|March 29, 2002
Myelin-derived glycolipids and animal models of Guillain-Barré syndromeKlaus V Toyka, Jürgen Zielasek, Guido Stoll
Pageof 13

Showing results (1-10 of 121) with videos related to

Sort By:
Pageof 13
Neurology|October 25, 2006
Ptosis in myasthenia gravis: extended fatigue and recovery bedside testKlaus V Toyka
Neurology|April 23, 2003
The pathogenesis of CIDP: rationale for treatment with immunomodulatory agentsKlaus V Toyka, Ralf Gold
The Lancet. Neurology|July 21, 2004
Immune-mediated components of hereditary demyelinating neuropathies: lessons from animal models and patientsRudolf Martini, Klaus V Toyka
Annals of the New York Academy of Sciences|November 1, 2017
Nerve Conduction Abnormalities and Neuromyotonia in Genetically Engineered Mouse Models of Human Hereditary NeuropathiesJürgen Zielasek, Klaus V Toyka
Annals of Neurology|July 3, 2003
Oculomotor signs in Lambert-Eaton myasthenic syndrome-coincidence with myasthenia gravisKlaus V Toyka, Christiane Schneider-Gold
European Neurology|January 23, 2002
Does Down's syndrome protect against multiple sclerosis?Franz X Weilbach, Klaus V Toyka
Neuroscience Letters|November 15, 2002
Differential blocking effects of the monoclonal anti-GQ1b IgM antibody and alpha-latrotoxin in the absence of complement at the mouse neuromuscular junctionBrigitte Buchwald, Raheleh Ahangari, Klaus V Toyka
Muscle & Nerve|February 15, 2007
Novel SOD1 N86K mutation is associated with a severe phenotype in familial ALSMarcus Beck, Michael Sendtner, Klaus V Toyka
The Cochrane Database of Systematic Reviews|December 14, 2012
Intravenous immunoglobulin for myasthenia gravisPhilippe Gajdos, Sylvie Chevret, Klaus V Toyka
Annals of Neurology|March 29, 2002
Myelin-derived glycolipids and animal models of Guillain-Barré syndromeKlaus V Toyka, Jürgen Zielasek, Guido Stoll
Pageof 13